Education
About Us
Working with TipRanks
Follow Us
InspireMD (NSPR)
NASDAQ:NSPR
NSPR Stock Chart & Stats
$1.88
$0.06(2.18%)
At close: 4:00 PM EST
$1.88
$0.06(2.18%)
Day’s Range― - ―
52-Week Range$1.59 - $3.80
Previous CloseN/A
Volume8.46K
Average Volume (3M)102.59K
Market Cap
$88.66M
Enterprise Value$99.83M
Total Cash (Recent Filing)$63.40M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta-0.21
Next Earnings
Mar 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding41,720,660
10 Day Avg. Volume68,719
30 Day Avg. Volume102,589
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)3.06
Price to Sales (P/S)15.73
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue12.83
Enterprise Value/Gross Profit51.51
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$5.00Price Target Upside165.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialInspireMD could be an attractive add-on for Boston or other big MedTech cardiovascular players.
Analyst RecommendationAnalyst recommends a Buy rating and a $5 price target.
Business GrowthInspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.
Market ShareBest-in-class data should result in fast share taking for InspireMD's CGuard.
Product PerformanceThe 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%, supporting a quick share shift within the TF-CAS market.
Regulatory ApprovalInspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.
Bears Say
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $1.59 and its highest was $3.80 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $88.66M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Mar 10, 2026 which is in 92 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on Nov 04, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.2.
How many shares outstanding does InspireMD have?
InspireMD has 41,720,660 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went down -7.424%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
InspireMD Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (165.96% Upside)
$5.00 (165.96% Upside)
Insider Transactions
Bought Shares
Worth $40.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.82%
12-Months-Change
Fundamentals
Return on Equity
-87.61%
Trailing 12-Months
Asset Growth
-40.10%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc. is a medical technology company focused on transforming the treatment of cardiovascular disease. The company specializes in developing and commercializing innovative solutions for coronary artery disease, particularly its proprietary MGuard technology, which incorporates a unique mesh design to enhance the safety and efficacy of vascular interventions. InspireMD operates primarily in the healthcare sector, targeting hospitals and medical professionals who require advanced tools for the treatment of patients with complex coronary conditions.
NSPR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth driven by the successful launch of CGuard Prime in the U.S. and strong international performance. Financially, the company showed improved gross margins and a strengthened cash position due to successful financing. However, increased operating expenses and a higher net loss were noted as challenges. Overall, the positive achievements and growth prospects outweighed the financial challenges.View all NSPR earnings summariesNSPR Stock 12 Month Forecast
Average Price Target
$5.00
▲(165.96% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
EDAP TMS
―
Vivani Medical
―
Xtant Medical Holdings
―